Latest News
Featured News
Scancell Receives FDA Fast Track Designation for iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Scancell Receives FDA Fast Track Designation for iSCIB1+
Scancell announces CFO Transition
Edison Report – Redesigning immunity: The next frontier in immuno-oncology
Scancell Financial Year 2026 Interim Results
H126: solid iSCIB1+ data underpins planned progress
Interim Results and Business Update
FDA clears global Phase III trial for iSCIB1+
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Notice of Interim Results and Investor Presentation
ESMO IO: Refining Standard of Care in Advanced Melanoma
CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive
SCOPE Data Update: 11 December 2025
No results found.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.